image 2 image 4
Skip Navigation Links
 Home 
 Congress Structure 
 Important Dates 
 Venue 
 Pre Registered 
 Hotel Info 
 Abstracts 
 Scientific Program 
 Social Program 
 Exhibition 
 Contact Us 
 Archive 
       XXIII Annual Congress of the Iranian Society of Ophthalmology        بـیــست و سومین کنــگــره سـالیـانه انـجـمـن چـشـم پـزشـکی ایـــران
مقاله Abstract


Title: The Effect of Bevacizumab (Avastin®) on Posterior Capsular Opacification after Phacoemulsification: A Randomized Clinical Trial.
Author(s): Mansour Rahimi, Mohammad Reza Talebnejad, Gholam Abbas Roustaei, Mahnaz Mosallaei
Presentation Type: Poster
Subject: Cornea and Anterior Segment
Others:
Presenting Author:
Name: Mansour Rahimi
Affiliation :(optional) Poustchi Ophthalmology Research Center, and Ophthalmology department, Shiraz, Iran.
E mail: mrahimi@sums.ac.ir
Phone:
Mobile: 09171117869
Purpose:

The aim of this study is to evaluate the possible effect of Bevacizumab (Avastin) on prevention of posterior capsular opacification after phacoemulsification.

Methods:

Sixty-eight patients were included in the study. Inclusion criteria were senile cataract and exclusion ones were history of diabetes mellitus, cardiovascular, cerebrovascular or thromboembolic disease and ocular pathologies. Patients underwent phacoemulsification and equal numbers of them were randomly assigned to either receive intracameral bevacizumab (ICB) 1.25 mg/0.05 ml or BSS as control. Digital retroillumination of the posterior capsule obtained 2 months and 1 year postoperatively. Image processing and calculating PCO score were done using an Objective System Capsule Analysis (OSCA).

Results:

At 2 months, a mean OSCA PCO score of 0.45061 ± 0.22419 was found for the ICB group and a score of 0.46449 ± 0.30933 was found for the control group. At 1 year, it was 0.78390 ± 0.15707 for the ICB group and 0.90807 ± 0.37180 for the control group. There were no significant difference of the mean OSCA PCO score between two groups at 2 month and 1 year postoperatively (p = 0.86 and p = 0.16 respectively). No patient underwent Nd: YAG laser capsulotomy during follow-up period.

Conclusion:

This is the first study on possible effects of bevacizumab on PCO. Although 1 year PCO score at the ICB group was less than control, the difference was not statistically significant. This lack of difference may be either due to shortness of follow-up or infectivity of intervention.

Attachment: 688Dr. Rahimi Poster.pptx





Skip Navigation Links
        صفحه اصلی
        ساختار کنگره
        تاریخ های مهم
        مکان برگزاری
        ثبت نام شدگان
        اطلاعات هتل - رزرو
        ارسال مقالات
        برنامه کنگره
        برنامه های جانبی
        نمایشگاه
        تماس با ما
        آرشیو کنگره سالهای گذشته
        جستجوی سخنران
 
Last News

  - بـیــست و سومین کنــگــره سـالیـانه انـجـمـن چـشـم پـزشـکی ایـــران